Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer. This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.

NCT Number	NCT07416240
Lead Sponsor	Hainan Cancer Hospital Collaborators: Frontiergate Biopharm（Hainan） Co., LTD
Conditions	Advanced Pancreatic Cancer
Enrollment	10 participants
Start Date	2026-02-18
Primary Completion	2028-02-18 (estimated)
Study Completion	2028-08-18 (estimated)
Updated on ClinicalTrials.gov	2026-02-18